Medicinal Chemistry
Target-based design and syntheses of new chemical entities for various therapeutic areas :
Tropical communicable and neglected diseases:
(a) Tuberculosis: inhibitors of FtsZ protein assembly, His G, isocitrate lyase (ICL), and malate synthase (MS)
(b) Leishmaniasis: trypanothione reductase (TR), ribose-5-phosphate, and HDAC inhibitors.
Non-communicable diseases:
(a) Diabetes: PTP1B, GOAT inhibitors;
(b) Inflammation: selective COX-2, COX-LOX dual inhibitors for rheumatoid arthritis and their implication in other disease control such as cancer and CNS disorder; and PDE-IVB inhibitors for asthma and COPD
(c) Cancer: antimitotic agents (second and third generation taxoids, epothiolones and eleutherobins), PKC inhibitors
(d) Cardiovascular: calcium channel blockers, HMG-CoA reductase inhibitors, endothelin receptor antagonists
Tropical communicable and neglected diseases:
(a) Tuberculosis: inhibitors of FtsZ protein assembly, His G, isocitrate lyase (ICL), and malate synthase (MS)
(b) Leishmaniasis: trypanothione reductase (TR), ribose-5-phosphate, and HDAC inhibitors.
Non-communicable diseases:
(a) Diabetes: PTP1B, GOAT inhibitors;
(b) Inflammation: selective COX-2, COX-LOX dual inhibitors for rheumatoid arthritis and their implication in other disease control such as cancer and CNS disorder; and PDE-IVB inhibitors for asthma and COPD
(c) Cancer: antimitotic agents (second and third generation taxoids, epothiolones and eleutherobins), PKC inhibitors
(d) Cardiovascular: calcium channel blockers, HMG-CoA reductase inhibitors, endothelin receptor antagonists
|
|
Site hosted and contents owned, maintained and updated by: Dr. AKC research group
Page Last Updated / Reviewed on: Feb 10, 2020
Page Last Updated / Reviewed on: Feb 10, 2020
